We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immediate Diagnosis Provided at POC for Cardiac Patients

By LabMedica International staff writers
Posted on 12 Oct 2009
A new biochip analyzer will help save cardiac patients lives by providing immediate diagnosis at the point of care (POC). More...
The technology is based on the concept of using a biochip as a reaction platform with multiple specific ligands (antibodies and antigens) attached at pre-defined sites on the surface.

The Evidence MultiStat biochip analyzer is a product of Randox (Crumlin, UK). In addition to cardiac tests, it offers arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids, and drugs of abuse. The Evidence MutiStat belongs to a family of flexible and reliable immunoassay analyzers. The largest member of the family is the Evidence, which has an output of 1,400 tests per hour.

The MutiStat system is suitable for emergency departments, cardiac units, doctor's surgeries, forensic units, rehabilitation units, and employee drug screening centers. The technology offers fully automated pipetting, incubation, washing, imaging, and report generation. This, together with a user-friendly touch screen and Windows-based software, enables the MultiStat to be used by nontechnical staff with little or no training.

The test menu can work with a wide range of sample matrix including urine and serum--plasma and whole blood are currently in development. The cardiac arrays include creatinine kinase-MB (CK-MB), fatty acid binding protein (FABP), myoglobin, and cardiac troponin. The drugs of abuse arrays include multiple analytes such as amphetamine, barbiturates, benzadiazepine, cannabinoids, and cocaine.

Cardiovascular disease is a progressive and complicated condition, covering a range of symptoms and biochemical processes that vary according to the patient. Multiple markers are therefore required to provide accurate diagnoses. The new Randox technology benefits patients with chest pains by rapidly identifying risk and enabling accurate clinical decisions.

Randox is a diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Its core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; recombinant proteins and antibodies.

Related Links:

Randox



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.